Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ASCENT
- 14 Aug 2018 Planned End Date changed from 1 Mar 2026 to 1 Jun 2026.
- 14 Aug 2018 Planned primary completion date changed from 1 Mar 2022 to 1 Jun 2022.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.